Retagliptin (Synonyms: SP2086) |
Catalog No.GC63170 |
레타글립틴(SP2086)은 선택적이고 경쟁적이며 경구 활성인 디펩티딜 펩티다제-4(DPP-4) 억제제입니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1174122-54-3
Sample solution is provided at 25 µL, 10mM.
Retagliptin (SP2086) is a selective, competitive and orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. Retagliptin can be used for type 2 diabetes mellitus (T2DM) research[1].
Retagliptin is a class of compound used for research of type 2 diabetes. Retagliptin inhibits the degradation of GLP-1, thus amplifying the incretin effect[1].
[1]. Avivit Cahn, et al. An update on DPP-4 inhibitors in the management of type 2 diabetes. Expert Opin Emerg Drugs. 2016 Dec;21(4):409-419.
Average Rating: 5
(Based on Reviews and 25 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *